David Persing - Cepheid Insider

CPHD -- USA Stock  

null 52.95  0.00  0.00%

Executive Vice President Chief Medical and Technology Officer, Director
Dr. David H. Persing M.D. Ph.D. is Executive Vice President Chief Medical and Technology Officer and Director of the Company
Age: 59  President Since 2005  Ph.D    
408 541-4191  www.cepheid.com
Persing first joined us as a director in May 2004, and became our Executive Vice President and Chief Medical and Technology Officer in August 2005. From 1999 to 2005, Dr. Persing was a research executive and Chief Scientific Officer at Corixa Corporationrationrationration, a Seattlebased biotechnology company, until its acquisition by GlaxoSmithKline. From 1990 to 1999 he was a member of the Clinical and Research Faculty of the Mayo Clinic in Rochester, Minnesota where he conducted research on hepatitis viruses, tickborne infections and molecular diagnostics. In 1992 he founded and directed the Molecular Microbiology Laboratory at Mayo Clinic. He has authored over 270 peerreviewed articles and has served as Editor in Chief for four textbooks on Molecular Diagnostics, the most recent of which was published by ASM press in 2011.

David Persing Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (0.06) % which means that it has lost $0.06 on every $100 spent on asset. This is way below average.
The company currently holds 281.63 M in liabilities with Debt to Equity (D/E) ratio of 0.76 which is about average as compared to similar companies. Cepheid has Current Ratio of 4.21 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and nonclinical markets. Cepheid (CPHD) is traded on NASDAQ in USA. It is located in 904 Caribbean Drive, Sunnyvale, CA 94089-1189, United States and employs 1,700 people.

Cepheid Leadership Team

Thomas Gutshall, Director
Robert Easton, Director
Glenn Steele, Director
Thomas Brown, Director
Warren Kocmond, COO
Jacquie Ross, Executive
Kerry Flom, EVP, Ph.D
Daniel Madden, President
Michael Fitzgerald, EVP
Peter Farrell, EVP
David Persing, President, Ph.D
Scott Campbell, President, Ph.D
Marc Haugen, President
John Bishop, Chairman
Cristina Kepner, Director
Hollings Renton, Director
Joseph Smith, President

Stock Performance Indicators

Current Sentiment - CPHD

Cepheid Investor Sentiment
Most of Macroaxis users are currently bullish on Cepheid. What is your opinion about investing in Cepheid? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Cepheid and Schmitt Industries. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.